Reviva Pharmaceuticals Holdings, Inc.RVPHNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -42.78% |
| Q2 2025 | -9.45% |
| Q1 2025 | -12.12% |
| Q4 2024 | -31.75% |
| Q3 2024 | 22.81% |
| Q2 2024 | -3.45% |
| Q1 2024 | -31.76% |
| Q4 2023 | -2.76% |
| Q3 2023 | -3.05% |
| Q2 2023 | 71.75% |
| Q1 2023 | -16.87% |
| Q4 2022 | 173.09% |
| Q3 2022 | -48.92% |
| Q2 2022 | -22.57% |
| Q1 2022 | 118.95% |
| Q4 2021 | 87.08% |
| Q3 2021 | 280.24% |
| Q2 2021 | -4.30% |
| Q1 2021 | 32.53% |
| Q4 2020 | 30805.76% |
| Q3 2020 | -97.38% |
| Q2 2020 | -86.55% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | -100.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |